Conavi Medical Files Amended Prospectus for Up to $15 Million Equity Offering to Fund U.S. Novasight Launch

Conavi Medical ( (TSE:CNVI) ) just unveiled an announcement.

Conavi Medical Corp. has filed an amended and restated final short form prospectus in connection with a previously announced public offering of common shares and pre-funded warrants, targeting gross proceeds of between $12 million and $15 million at a price of $0.45 per share (or $0.44999 per pre-funded warrant). The financing, conducted on a commercially reasonable efforts basis by Bloom Burton Securities Inc., is intended to fund U.S. FDA 510(k) clearance and a targeted U.S. market release of the next-generation Novasight Hybrid system, as well as provide working capital and general corporate funds. The offering, which may close in one or more tranches around January 13, 2026, remains subject to regulatory and TSX Venture Exchange approvals, and includes standard agency compensation through cash fees and options, underscoring the company’s push to strengthen its capital position and accelerate commercialization in the cardiovascular imaging market.

The most recent analyst rating on (TSE:CNVI) stock is a Buy with a C$1.00 price target. To see the full list of analyst forecasts on Conavi Medical stock, see the TSE:CNVI Stock Forecast page.

More about Conavi Medical

Conavi Medical Corp. is a Toronto-based, commercial-stage medical device company that designs, manufactures and markets imaging technologies used to guide common minimally invasive cardiovascular procedures. The company’s product portfolio includes its Novasight Hybrid system, with a current strategic focus on advancing next-generation intravascular imaging solutions and expanding its presence in key markets such as the United States.

Average Trading Volume: 23,628

Technical Sentiment Signal: Sell

Current Market Cap: C$25.38M

Find detailed analytics on CNVI stock on TipRanks’ Stock Analysis page.